DrugCite
Search

SLOW K

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Slow K Adverse Events Reported to the FDA Over Time

How are Slow K adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Slow K, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Slow K is flagged as the suspect drug causing the adverse event.

Most Common Slow K Adverse Events Reported to the FDA

What are the most common Slow K adverse events reported to the FDA?

Hyperkalaemia
41 (4.59%)
Muscle Spasms
25 (2.8%)
Vomiting
21 (2.35%)
Gastric Lavage
20 (2.24%)
Cardio-respiratory Arrest
18 (2.02%)
Ventricular Fibrillation
17 (1.9%)
Drug Ineffective
15 (1.68%)
Blood Potassium Decreased
14 (1.57%)
Suicide Attempt
14 (1.57%)
Loss Of Consciousness
13 (1.46%)
Apnoea
12 (1.34%)
Show More Show More
Asthma
12 (1.34%)
Cardiac Arrest
12 (1.34%)
Pallor
12 (1.34%)
Overdose
11 (1.23%)
Cerebral Infarction
10 (1.12%)
Resuscitation
10 (1.12%)
Diarrhoea
9 (1.01%)
Oedema Peripheral
9 (1.01%)
Renal Impairment
9 (1.01%)
Syncope
9 (1.01%)
Endoscopy Upper Gastrointestinal Tr...
8 (.9%)
Fluid Retention
8 (.9%)
Gastritis Erosive
8 (.9%)
Haemodialysis
8 (.9%)
Ventricular Tachycardia
8 (.9%)
Abdominal Pain
7 (.78%)
Blood Creatinine Increased
7 (.78%)
Dyspepsia
7 (.78%)
Dyspnoea
7 (.78%)
Intentional Overdose
7 (.78%)
Liver Disorder
7 (.78%)
Platelet Count Decreased
7 (.78%)
Atrial Fibrillation
6 (.67%)
Fatigue
6 (.67%)
Hepatic Function Abnormal
6 (.67%)
Hypotension
6 (.67%)
Melaena
6 (.67%)
Pulmonary Oedema
6 (.67%)
Pyrexia
6 (.67%)
Cardiac Operation
5 (.56%)
Chromaturia
5 (.56%)
Condition Aggravated
5 (.56%)
Drug Interaction
5 (.56%)
Gastritis Haemorrhagic
5 (.56%)
Ileus
5 (.56%)
Nervousness
5 (.56%)
Upper Gastrointestinal Haemorrhage
5 (.56%)
Abdominal Pain Upper
4 (.45%)
Accidental Overdose
4 (.45%)
Alanine Aminotransferase Increased
4 (.45%)
Aspartate Aminotransferase Increase...
4 (.45%)
Blood Pressure Diastolic Decreased
4 (.45%)
Blood Pressure Increased
4 (.45%)
Coronary Artery Bypass
4 (.45%)
Cyanosis
4 (.45%)
Decreased Appetite
4 (.45%)
Dehydration
4 (.45%)
Depression
4 (.45%)
Disease Progression
4 (.45%)
Gallbladder Operation
4 (.45%)
Gastrectomy
4 (.45%)
Gastric Disorder
4 (.45%)
Hunger
4 (.45%)
Hyperphagia
4 (.45%)
Intermittent Positive Pressure Brea...
4 (.45%)
Interstitial Lung Disease
4 (.45%)
Intestinal Adenocarcinoma
4 (.45%)
Lung Abscess
4 (.45%)
Mitral Valve Repair
4 (.45%)
Poor Quality Drug Administered
4 (.45%)
Primary Hyperaldosteronism
4 (.45%)
Pulse Absent
4 (.45%)
Renal Failure Acute
4 (.45%)
Respiratory Failure
4 (.45%)
Retching
4 (.45%)
Shock
4 (.45%)
Toxic Epidermal Necrolysis
4 (.45%)
Urinary Tract Infection
4 (.45%)
Weight Decreased
4 (.45%)
Asthenia
3 (.34%)
Blood Aldosterone Increased
3 (.34%)
Blood Pressure Decreased
3 (.34%)
Extrasystoles
3 (.34%)
Feeling Abnormal
3 (.34%)
Hypokalaemia
3 (.34%)
Incorrect Dose Administered
3 (.34%)
Malaise
3 (.34%)
Myalgia
3 (.34%)
Pain In Extremity
3 (.34%)
Pancytopenia
3 (.34%)
Rash
3 (.34%)
Schizophrenia
3 (.34%)
Tachycardia
3 (.34%)
White Blood Cell Count Decreased
3 (.34%)
Accidental Exposure
2 (.22%)
Acidosis
2 (.22%)
Adrenal Neoplasm
2 (.22%)
Adrenalectomy
2 (.22%)
Allergic Bronchitis
2 (.22%)
Anaphylactic Shock
2 (.22%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Slow K, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Slow K is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Slow K

What are the most common Slow K adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Slow K, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Slow K is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Slow K According to Those Reporting Adverse Events

Why are people taking Slow K, according to those reporting adverse events to the FDA?

Hypokalaemia
208
Drug Use For Unknown Indication
88
Blood Potassium Decreased
40
Product Used For Unknown Indication
31
Electrolyte Substitution Therapy
25
Prophylaxis
21
Show More Show More
Mineral Supplementation
20
Muscle Spasms
17
Cardiac Failure Congestive
8
Hypertension
6
Oedema Peripheral
6
Cardiac Failure
5
Suicide Attempt
5
Multiple Myeloma
5
Crohns Disease
4
Ileus Paralytic
4
Insomnia
4
Oedema
4
Supplementation Therapy
4
Nephrotic Syndrome
4
Intentional Overdose
4
Myocardial Ischaemia
3
Electrolyte Imbalance
3
Alkalosis
3
Cardiac Failure Chronic
3
Anaemia
3
Atrial Fibrillation
3
Ill-defined Disorder
2
Cardiomyopathy
2
Diabetes Mellitus
2
Swelling
2
Blood Potassium
2
Hyperkalaemia
2
Vitamin Supplementation
2
Myalgia
2
Off Label Use
2
Concomitant Disease Aggravated
1
Sjogrens Syndrome
1
Hypoglycaemia
1
Pulmonary Arterial Hypertension
1
Aplastic Anaemia
1
Blood Potassium Abnormal
1
Routine Health Maintenance
1
Pain In Extremity
1
Hyponatraemia
1

Slow K Case Reports

What Slow K safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Slow K. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Slow K.